inosine-diphosphate and Liver-Diseases

The available drugs for the treatment of chronic liver affections (the adequate model is chronic hepatitis C) include agents of metabolic therapy, whose efficacy is not always enough, that required the search for original mitochondrial substrates on the basis of succinate. Such agents were composed as a pharmaceutical group named "Substrates of Energetic Metabolism" or "Substrate Antihypoxants". The review presents the description of the pharmacological effects of remaxole and cytoflavin, evident from lower levels of active metabolites of oxygen that increases the clinical efficacy of the therapy. Their role in the metabolic reactions in chronic liver affections is exclusive and rather actual.

Topics: Apoptosis; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Glutathione Disulfide; Hepatitis C, Chronic; Humans; Inosine Diphosphate; Lipid Peroxidation; Liver Diseases; Niacinamide; Protective Agents; Succinates

The results of the experiments with use of isoniazid and its metabolites showed that in the liver of rats isoniazid induced albuminous degeneration with stroma inflammation and hepatocyte necrosis, monoacetylhydrazine induced fatty hepatosis, acetylisoniazid induced fatty hepatosis with stroma inflammation and hepatocyte necrosis and isonicotinic acid induced granular degeneration. Piracetam proved to be efficient in fatty hepatosis. Riboxin and dibunol were efficient in hepatitis. The drugs used clinically as liver protectors, i.e. cobamamide, pyridoxal phosphate and methionine had no protective action in liver affections induced by isoniazid whereas catergen, lipamide, dipromonium and methindione even aggravated such affections.

Topics: Animals; Butylated Hydroxytoluene; Chemical and Drug Induced Liver Injury; Female; Inosine Diphosphate; Isoniazid; Liver; Liver Diseases; Piracetam; Rats